Holen Sie sich die Stockscreener-App
12.67
3.28%
-0.43
Schlusskurs vom Vortag:
$13.10
Offen:
$12.51
24-Stunden-Volumen:
613.34K
Relative Volume:
1.03
Marktkapitalisierung:
$878.01M
Einnahmen:
$62.71M
Nettoeinkommen (Verlust:
$-112.51M
KGV:
-8.3907
EPS:
-1.51
Netto-Cashflow:
$-96.01M
1W Leistung:
+0.56%
1M Leistung:
+9.13%
6M Leistung:
+0.72%
1J Leistung:
+39.08%
1-Tages-Spanne:
$12.33
$12.91
1-Wochen-Bereich:
$12.28
$13.44
52-Wochen-Spanne:
$8.21
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Vergleichen Sie ZYME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
12.67 | 878.01M | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade) (ZYME) - Seeking Alpha
Transcript : Zymeworks Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - marketscreener.com
ZYMEZymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results - mx.advfn.com
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge - MSN
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High? - MSN
Zymeworks Inc. (NYSE:ZYME) Shares Acquired by Nuveen Asset Management LLC - Defense World
Zymeworks gets China's conditional approval for biliary tract cancer treatment - MSN
Zymeworks Announces NMPA Approval of Zanidatamab in China - GlobeNewswire
Zymeworks gets China's conditional nod for BeOne-partnered cancer treatment - Seeking Alpha
Zymeworks Inc. Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-High expression (IHC3+ Biliary Tract Cancer - marketscreener.com
Zymeworks’ Zanidatamab Receives NMPA Approval in China for HER2+ Biliary Tract Cancer - TipRanks
Zymeworks (ZYME) Receives China's Approval for Zanidatamab in Cancer Treatment | ZYME Stock News - GuruFocus
Zymeworks' Zanidatamab Approved in China for HER2-High Expression Biliary Tract Cancer - marketscreener.com
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - Yahoo Finance
Zymeworks Inc. announces the closing of its previously announced underwritten public offering - McCarthy Tétrault
What is HC Wainwright’s Forecast for Zymeworks Q2 Earnings? - Defense World
Zymeworks Showcases Oncology Advances at Major Conferences - TipRanks
Zymeworks Inc. Showcases Azymetric™ Platform and Clinical Progress of Ziihera® at ASCO and ESMO Conferences - Nasdaq
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewswire
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewswire Inc.
TD Cowen Initiates Coverage on Zymeworks (NYSE:ZYME) - Defense World
TD Securities Initiates Coverage on Zymeworks (NYSE:ZYME) - Defense World
Zymeworks Announces Participation in Upcoming Investor Conferenc - GuruFocus
Zymeworks to Engage Investors at Upcoming Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Zymeworks Inc. Announces Upcoming Participation in Key Investor Conferences in June 2025 - Nasdaq
Zymeworks Lines Up Triple Conference Presence: Jefferies, Goldman Sachs, and Citi Healthcare Events - Stock Titan
Zymeworks Inc. (NYSE:ZYME) Shares Acquired by Northern Trust Corp - Defense World
TD Securities Initiates Coverage of Zymeworks (ZYME) with Buy Recommendation - Nasdaq
Zymeworks (ZYME) Initiated as a Buy by TD Cowen Due to Strong Pi - GuruFocus
Zymeworks initiated with a Buy at TD Cowen on Ziihera's opportunities - Seeking Alpha
Zymeworks (ZYME) Receives New Buy Rating from TD Securities | ZYME Stock News - GuruFocus
TD Cowen Initiates Coverage on Zymeworks With Buy Rating - marketscreener.com
Zymeworks (ZYME) Gains Favor with Buy Rating from TD Cowen | ZYM - GuruFocus
Zymeworks Presents Preclinical Data on ZW1528 at the American Th - GuruFocus
Zymeworks (ZYME) Reveals Promising Preclinical Results for ZW152 - GuruFocus
Zymeworks Shows Positive Preclinical Data for Experimental Respiratory Imflammation Treatment - marketscreener.com
Zymeworks Unveils Promising Preclinical Data for Novel Respiratory Treatment - TipRanks
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference - The Manila Times
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference | ZYME Stock News - GuruFocus
The Manufacturers Life Insurance Company Sells 1,089 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Price T Rowe Associates Inc. MD Raises Stock Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet - NewsBreak: Local News & Alerts
Analyst Forecasts For Zymeworks Inc. (NASDAQ:ZYME) Are Surging Higher - Yahoo Finance
Analysts Just Shipped A Stunning Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates - simplywall.st
Zymeworks Reports Q1 2025 Financial Results and R&D Progress - TipRanks
Zymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call Transcript - Insider Monkey
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates - MSN
Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue S - GuruFocus
Dimensional Fund Advisors LP Purchases 123,240 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... - Yahoo Finance
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):